Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 6, 2023BMJOpen Access

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

QSQingyang ShiSun Yat-sen UniversityKNKailei NongSichuan UniversityPVPer Olav VandvikUniversity of Oslo

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shi et al. (2023) studied this question.

synapsesocial.com/papers/69daaf36aae38ff6ad835a88https://doi.org/10.1136/bmj-2022-074068

Topics

Heart failureHFrEF treatmentSGLT2 inhibitors in heart failureHFpEF management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1International consensus definitions of clinical trial outcomes for kidney failure: 20202020 · 126 citations
  2. 2Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials2021 · 696 citations
  3. 3Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses2021 · 27 citations
  4. 4Meta-Analysis of Rare Binary Adverse Event Data2012 · 139 citations
  5. 5Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses2020 · 780 citations